Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (191-200 of 337) with videos related to

Pageof 34
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2009
Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, ThailandWanitchaya Kittikraisak, Frits van Griensven, Michael Martin, et al.
Frontiers in Immunology|December 13, 2019
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector CellsLeigh Fisher, Melissa Zinter, Sherry Stanfield-Oakley, et al.
Viruses|October 26, 2021
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 TransmissionDavid A Swan, Ashish Goyal, Chloe Bracis, et al.
The Journal of Infectious Diseases|August 6, 2004
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160Deborah Lee, Barney S Graham, Ya-Lin Chiu, et al.
Plos One|September 15, 2015
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated MenZoe Moodie, Barbara Metch, Linda-Gail Bekker, et al.
NPJ Vaccines|April 29, 2024
Realising the potential of correlates of protection for vaccine development, licensure and use: short summaryDeborah F King, Helen Groves, Charlie Weller, et al.
The Lancet. Infectious Diseases|February 25, 2014
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyGlenda E Gray, Zoe Moodie, Barbara Metch, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trialsMichal Juraska, Craig A Magaret, Jason Shao, et al.
American Journal of Epidemiology|August 21, 2025
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-upEthan Ashby, Holly Janes, Dean Follmann, et al.
Plos Computational Biology|February 22, 2020
Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trialsDaniel B Reeves, Yunda Huang, Elizabeth R Duke, et al.
Pageof 34

Showing results (191-200 of 337) with videos related to

Sort By:
Pageof 34
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2009
Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, ThailandWanitchaya Kittikraisak, Frits van Griensven, Michael Martin, et al.
Frontiers in Immunology|December 13, 2019
Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector CellsLeigh Fisher, Melissa Zinter, Sherry Stanfield-Oakley, et al.
Viruses|October 26, 2021
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 TransmissionDavid A Swan, Ashish Goyal, Chloe Bracis, et al.
The Journal of Infectious Diseases|August 6, 2004
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160Deborah Lee, Barney S Graham, Ya-Lin Chiu, et al.
Plos One|September 15, 2015
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated MenZoe Moodie, Barbara Metch, Linda-Gail Bekker, et al.
NPJ Vaccines|April 29, 2024
Realising the potential of correlates of protection for vaccine development, licensure and use: short summaryDeborah F King, Helen Groves, Charlie Weller, et al.
The Lancet. Infectious Diseases|February 25, 2014
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyGlenda E Gray, Zoe Moodie, Barbara Metch, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2018
Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trialsMichal Juraska, Craig A Magaret, Jason Shao, et al.
American Journal of Epidemiology|August 21, 2025
Validating and leveraging non-SARS-CoV-2 respiratory infection as a negative control outcome in a phase 3 COVID-19 vaccine trial with extended observational follow-upEthan Ashby, Holly Janes, Dean Follmann, et al.
Plos Computational Biology|February 22, 2020
Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trialsDaniel B Reeves, Yunda Huang, Elizabeth R Duke, et al.
Pageof 34